Cargando…
Immunopathology of galectin-3: an increasingly promising target in COVID-19
The pandemic brought on by the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has become a global health crisis, with over 22 million confirmed cases and 777,000 fatalities due to coronavirus disease 2019 (COVID-19) reported worldwide. The major cause of fatality in infected...
Autores principales: | Caniglia, John L., Asuthkar, Swapna, Tsung, Andrew J., Guda, Maheedhara R., Velpula, Kiran K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536583/ https://www.ncbi.nlm.nih.gov/pubmed/33082935 http://dx.doi.org/10.12688/f1000research.25979.2 |
Ejemplares similares
-
A potential role for Galectin-3 inhibitors in the treatment of COVID-19
por: Caniglia, John L., et al.
Publicado: (2020) -
Galectin-1 activates carbonic anhydrase IX and modulates glioma metabolism
por: Guda, Maheedhara R., et al.
Publicado: (2022) -
Targeting RGS4 Ablates Glioblastoma Proliferation
por: Guda, Maheedhara R., et al.
Publicado: (2020) -
B7-H3 in Medulloblastoma-Derived Exosomes; A Novel Tumorigenic Role
por: Purvis, Ian J., et al.
Publicado: (2020) -
Beyond glucose: alternative sources of energy in glioblastoma
por: Caniglia, John L., et al.
Publicado: (2021)